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Activin signalling has a necessary function in Xenopus early
development
Steven Dyson and J.B. Gurdon
The first signalling event in Xenopus development is the
mesoderm-forming (or Nieuwkoop) induction, starting
three hours after fertilization [1]. Two prime candidates
for the molecule that mediates this signalling are activin
[2] and Vg1 [3], both members of the transforming growth
factor b (TGFb) family. Because genetic methods are not
available for amphibian studies, ‘dominant-negative’
truncated receptors have been used in studying signalling
molecules such as the receptors for fibroblast and
platelet-derived growth factors (FGF and PDGF) [4,5]. The
truncated receptors bind to, and prevent signalling from,
endogenous receptors. Activin is a potent mesoderm
inducer in vitro, and the severe phenotype obtained using
a dominant-negative activin receptor in Xenopus [6],
coupled with evidence from fish [7], suggested that
activin is essential for development. However, a
dominant-negative receptor for activin blocked the
activity of other TGFb family members in Xenopus, most
notably Vg1 [8], and activin ‘knock-out’ mice are
essentially wild-type in phenotype [7]; these two findings
cast doubt on the idea of a function for activin in early
development. We have designed a new receptor
construct which can selectively block the function of
activin but not of Vg1, and we have used it to show that
activin has an essential role in vivo in Xenopus early
development. We conclude that activin, or a close relative
that has yet to be described, is required for normal
development.
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Results and discussion
Previous attempts to assess the role of activin using a trun-
cated activin type IIB receptor were deemed inconclusive
when it was shown that the effects of this receptor were
not specific to activin [8]: it also blocked the signalling of
other TGFb family members, most notably Vg1. We spec-
ulated that a dominant-negative receptor which lacked a
transmembrane domain might be more specific. It would
still have a ligand-binding domain and therefore the ability
to bind to activin and block its signalling, but might no
longer be able to interfere with other receptors at the cell
surface. We therefore designed a new construct consisting
only of the ligand-binding domain of the activin type IIB
receptor (ActRIIBexd; see Fig. 1). This construct differs
from previous dominant-negative receptors in that it lacks
both intracellular and transmembrane domains and is
therefore likely to be secreted.
We determined whether our new construct can in fact
block activin signalling whilst not interfering with Vg1 sig-
nalling. The animal cap assay has long been used as an
assay of mesoderm induction in vitro [1]. Animal cap cells
are normally fated to become ectodermal tissue, but when
treated with activin or Vg1 they differentiate into mesoder-
mal tissue. We used this assay system to test the specificity
of our receptor construct. Injection of mRNA synthesized
in vitro that encodes either activin or Vg1 induces a range
of early mesodermal markers in animal caps (Fig. 2, lanes 3
and 6). Addition of ActRIIBexd mRNA (exd in Fig. 2, lane
5) blocks gene induction by activin but has no effect on
gene induction by Vg1 (Fig. 2, lane 8). We also tested two
other TGFb family members that are candidate mesoderm
inducers, Xnr1 and Xnr2 [9]. Xnr1, like activin and Vg1,
induces a range of early mesodermal markers (Fig. 2, lane
Figure 1
Composition of the ActRIIBexd dominant-negative receptor.
Comparison of the dominant-negative ActRIIBexd and ActRIIBdn [4],
the latter containing the transmembrane domain, with wild-type ActRIIB
[16]. ActRIIBexd was derived from ActRIIB as described [16], but it
lacks codon 51 and differs in codon 52. However, this form of ActRIIB
is known to be functionally equivalent to the published ActRIIB [16].
Numbers indicate the amino-acid residues in each construct.
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9) and this induction is not blocked by ActRIIBexd (Fig. 2,
lane 10). Xnr2 behaves in a similar manner (data not
shown). BMP-4, another TGFb family member which is
able to induce some mesodermal genes, was also tested.
BMP-4 signalling was reduced by ActRIIBexd to only
70 % of the level seen with BMP-4 alone, under conditions
in which activin signalling was less than 5 % of normal.
These results clearly demonstrate that ActRIIBexd selec-
tively blocks activin or activin-like molecules. We have
further shown that ActRIIBexd is indeed more specific
than a standard dominant-negative activin receptor (dn in
Fig. 2). This previously described receptor [4] blocks sig-
nalling by activin (Fig. 2, lane 4) and greatly reduces Vg1
signalling (Fig. 2, lane 7). Therefore, we have generated a
novel dominant-negative activin receptor which, unlike
previous ones, can selectively and specifically block activin
signalling.
We can now determine whether activin has a role in
developing Xenopus embryos. Embryos at the 4-cell stage
were injected equatorially with mRNA encoding the
ActRIIBexd construct (the same dose as in the experi-
ments shown in Fig. 2). These embryos were allowed to
develop until the tadpole stage (Fig. 3a,b). The injected
embryos (Fig. 3b) appear severely defective when com-
pared with uninjected controls (Fig. 3a); they lack head
structures, as judged morphologically, suggesting a defi-
ciency in anterior differentiation. We next determined
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ActRIIBexd disrupts normal Xenopus development and inhibits Xbra
induction. ActRIIBexd was injected equatorially into each blastomere at
the 4-cell stage to a total of 1 ng. These embryos (b) were cultured until
control embryos (a) had reached the tadpole stage (stage 35). (c) Other
embryos were treated in the same manner but were frozen at
developmental stages 9, 9.5,10,10.25, 10.5, 11, 12 or 13 for RNase
protection analysis, and were probed for Xbra, with FGF receptor RNA
serving as a loading control. Each data point represents RNA from eight
embryos obtained in two independent experiments. Quantitation was
done using a phosphoimager with image-quant software. In (d), the
results shown in (c) are compared, showing the strong early inhibition of
early Xbra induction by ActRIIBexd.
Figure 2
ActRIIBexd is a dominant-negative receptor
highly specific to activin signalling. Activin
mRNA (4 pg; lanes 3–5), bVg1 mRNA (50 pg;
lanes 6–8), or Xnr1 mRNA ( 500 pg; lanes
9,10) was injected into the animal pole of each
blastomere of 2-cell embryos. These amounts
were chosen to give an induction of early
genes in animal caps equivalent to one whole
embryo (we; lane 1). Embryos were co-injected
with 1 ng of mRNA coding for the ActRIIBexd
construct (exd; lanes 5, 8 and 10) or 1 ng of
mRNA for the ActRIIBdn construct (dn; lanes 4
and 7) [6]. Animal caps were dissected at the
blastula stage and cultured until the early
gastrula stage (stage 10.5) when they were
frozen for RNase protection analysis. Lane 2
shows uninjected animal caps (ac) as a control.
Lanes 3–8 show animal caps injected as
indicated. Each sample was probed for Xbra
[10], Eomes [17], Chordin [18] and Xgsc [19],
with FGF receptor as a loading control.
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whether activin plays a role in mesoderm formation.
There are two possible roles for activin: it could be
involved either directly in the initial mesoderm induction
or in the subsequent mesoderm maintenance and pattern-
ing. To distinguish between these possibilities, we inves-
tigated the effects of ActRIIBexd on the induction of
Xbrachyury (Xbra), an immediate early (independent of
protein synthesis) pan-mesodermal gene marker [10]. A
reduction in early Xbra expression would indicate a role
for activin in mesoderm induction, whereas later repres-
sion of Xbra, after its initial induction, would suggest a
role for activin in mesoderm maintenance or patterning.
Embryos were treated as in Figure 3b, but samples were
removed at timepoints between late blastula and late gas-
trula stages and assayed for Xbra expression by RNase
protection. These timepoints correspond to the period of
initial Xbra expression [10]. The induction of Xbra when
activin signalling has been blocked by ActRIIBexd
appears to be delayed, compared with wild-type, by
approximately half a developmental stage (1–2 hours at
23 °C; see Fig. 3c). Further analysis shows that blocking
activin signalling with ActRIIBexd reduces the initial
induction of Xbra (stage 9.5) to 20 % of the wild-type
level (Fig. 3d). This result indicates a role for activin in
initial mesoderm induction. 
The fact that wild-type levels of induction are subsequently
reached between stages 10.5 and 11 (Fig. 3d) suggests that
there are mechanisms that can compensate for the lack of
activin signalling but that they take time to operate.
Clearly, the compensation is not sufficient to permit normal
development. Degenerate or compensatory mechanisms
are common in development: for example, members of the
myogenic family of transcription factors are thought to be
able to autoregulate their activity by binding directly to
their own promoters (see [11] for review). There is also evi-
dence that Xbra can induce expression of the eFGF gene,
which can, in turn, promote the maintenance of Xbra
expression [12]. In conclusion, we have shown that blocking
activin signalling substantially affects embryo development,
and the inhibition of early Xbra induction implicates activin
in mesoderm induction.
It is striking to contrast the phenotype we obtain by block-
ing activin signalling (Fig. 3b) with that obtained by
blocking FGF signalling [4]. As we have shown, knocking
out activin signalling generates embryos with reduced
anterior structures, whilst knocking out FGF signalling
gives embryos with reduced posterior structures [4]. This
would suggest complementary roles for activin and FGF,
with activin involved in mesoderm formation and FGF in
mesoderm maintenance. It may seem surprising that fol-
listatin, which binds to and counteracts activin, does not
cause the anterior defect seen with our dominant-negative
construct [13]. However, follistatin has been shown to
bind to BMP-4 as well as to activin [14,15], and the poste-
rior defects seen with follistatin could be due to blocking
BMP-4 signalling. Furthermore, because BMP-4 has ven-
tralizing activity, blocking BMP-4 signalling might be
expected to reduce posterior structures.
To further demonstrate the role of activin in Xenopus
development and the specificity of our construct, we have
attempted to rescue the ActRIIBexd-injected phenotype
with activin mRNA. Embryos were injected with
ActRIIBexd alone, or with ActRIIBexd and increasing
doses of activin mRNA, and cultured until the tadpole
stage (stage 35). A low dose of activin mRNA (Fig. 4c)
leads to a partial rescue of the ActRIIBexd phenotype
shown in Figure 4b. A higher dose of activin mRNA com-
pletely rescues the phenotype (Fig. 4d), comparable to
the control phenotype (Fig. 4a). These results show that
activin can indeed rescue the phenotype obtained by
blocking activin signalling. The dose-response nature of
these results suggests that a very low concentration of
activin in vivo is required for normal development.
ActRIIBexd blocks this and therefore impairs normal
development. Addition of exogenous activin mRNA can
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Activin mRNA rescues normal development in ActRIIBexd-injected embryos. (a) Uninjected control embryos. The embryos in (b) were treated as in
Figure 3b, but those in (c) and (d) were co-injected with 1 ng ActRIIBexd and with 1 pg (c) or 10 pg (d) of activin mRNA, respectively. The
embryos shown are representative of the phenotype observed.
titrate out the effects of ActRIIBexd and, at the correct
dose, rescue the embryos.
Conclusions
From the results we have presented here, we conclude
that blocking activin signalling severely disrupts Xenopus
development and that activin, or an activin-like molecule,
does indeed play an essential role in mesoderm induction.
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